Simcere Pharma (SCR) Misses Street's Q1 Views
More News related to SCR
- SCOR combines growth and profitability to generate a net income of EUR 278 million in the first nine months of 2009, with shareholders' equity increasing to EUR 3.8 billion (EUR 20.84 per share)
- Simcere Pharmaceutical Group to Announce 2009 Third Quarter Earnings on Monday, November 16, 2009
- Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
- Susquehanna Upgrades Simcere Pharmaceutical Group (SCR) to Positive; Raises FY10-12 Estimates
- Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Simcere Pharmaceutical Group (NYSE: SCR) reports Q1 EPS of $0.06, 11 cents lower than the analyst estimate of $0.17. Revenue for the quarter was $64.8 million, versus the consensus of $69.87 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
